Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

被引：10

作者：

Kaneko, Tetsuya ^{[1
,2
,3
,4
]}

Okamura, Koichi ^{[2
]}

Yonemoto, Yukio ^{[2
,3
]}

Okura, Chisa ^{[2
]}

Suto, Takahito ^{[2
]}

Tachibana, Masahiro ^{[2
]}

Sakane, Hideo ^{[1
,2
]}

Inoue, Makoto ^{[3
]}

Chikuda, Hirotaka ^{[2
]}

机构：

[1] Japan Redcross Soc Fukaya Red Cross Hosp, Dept Orthopaed Surg, Saitama, Japan

[2] Gunma Univ, Dept Orthopaed Surg, Grad Sch Med, 3-39-22 Showamachi, Maebashi, Gumma, Japan

[3] Inoue Hosp, Dept Orthopaed Surg & Rheumatol, Takasaki, Gumma, Japan

[4] Fukaya Seikeigeka Clin, Dept Orthopaed Surg, Fukaya, Saitama, Japan

来源：

JOURNAL OF EXPERIMENTAL ORTHOPAEDICS | 2019年 / 6卷 / 01期

关键词：

Osteoporosis; Denosumab; Bisphosphonate; Rheumatoid arthritis; Fragility fractures; POSTMENOPAUSAL WOMEN; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; DISEASE-ACTIVITY; DOUBLE-BLIND; OSTEOPOROSIS; 12-MONTH; GLUCOCORTICOIDS; MULTICENTER; IBANDRONATE;

D O I：

10.1186/s40634-019-0211-7

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Background To compare the efficacy of 12-month denosumab treatment on bone mineral density (BMD) and bone turnover markers (BTMs) between treatment-naive osteoporosis patients with rheumatoid arthritis (RA) and those with previous bisphosphonate (BP) therapy. Methods A total of 36 RA patients with osteoporosis completed 12-month follow-up. Twenty-five patients were osteoporotic treatment-naive (naive group), and 11 patients were previously treated with BPs (switch group) (average 7.9 years). BMD and BTMs were measured before and 6 and 12 months after treatment. Results BTM levels were higher in the naive group at baseline. However, the same level of suppression was achieved at 6 months in both groups. Spine BMD increased significantly in both groups. There was no significant difference in the mean percent changes of BMD of the spine (naive group: 6.8 +/- 0.8, switch group: 5.1 +/- 1.5), femoral neck (2.9 +/- 1.4, 2.9 +/- 1.3), and total hip (1.7 +/- 0.9, 1.4 +/- 1.1) between these two groups at 12 months. Conclusions The effects of denosumab on BMD and BTMs of the switch group after long-term BP treatment are comparable to those of the naive group in RA patients. Thus, switching BPs to denosumab is one of the useful options to treat osteoporosis with RA.

引用

页数：8

共 45 条

[1]

Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100

[2] Denosumab in treatment-naive and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers [J].

Anastasilakis, Athanasios D. ;

Polyzos, Stergios A. ;

Efstathiadou, Zoe A. ;

Sauvidis, Matthaios ;

Sakellariou, Grigorios T. ;

Papatheoclorou, Athanasios ;

Kokkoris, Panagiotis ;

Makras, Polyzois .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (10) :1291-1297

[3] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[4]

Benucci M, 2009, CLIN EXP RHEUMATOL, V27, P567

[5]

Bertoldi L., 2013, ISRN RHEUMATOL, V2013, DOI [10.1155/2013/708323, DOI 10.1155/2013/708323]

[6]

Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/jbmr.080901, 10.1359/JBMR.0809010]

[7] Dexamethasone induces caspase activation in murine osteoblastic MC3T3-E1 cells [J].

Chua, CC ;

Chua, BHL ;

Chen, ZY ;

Landy, C ;

Hamdy, RC .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1642 (1-2) :79-85

[8] Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis [J].

Cohen, Stanley B. ;

Dore, Robin K. ;

Lane, Nancy E. ;

Ory, Peter A. ;

Peterfy, Charles G. ;

Sharp, John T. ;

van der Heijde, Desiree ;

Zhou, Lifen ;

Tsuji, Wayne ;

Newmark, Richard .

ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1299-1309

[9] Management of glucocorticoid-induced osteoporosis [J].

Compston, Juliet .

NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (02) :82-88

[10]

den Uyl D, 2011, CLIN EXP RHEUMATOL, V29, pS93

← 1 2 3 4 5 →